Sessions are scheduled in local time (CEST)

Displaying One Session

Hamburg Hall Industry Satellite Symposium
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Room
Hamburg Hall
Chairs
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin (Madrid, Spain)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Welcome and introductions (ID 498)

Lecture Time
11:30 - 12:30
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer (ID 499)

Lecture Time
12:30 - 12:30
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer (ID 500)

Lecture Time
12:30 - 12:30
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer (ID 501)

Lecture Time
12:30 - 12:30
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Shared decision-making in HR-positive, HER2-negative early breast cancer: Enhancing patient-provider communication (ID 502)

Lecture Time
12:30 - 12:30
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)
AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?

Questions and take-home messages (ID 503)

Lecture Time
12:30 - 12:30
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • All Speakers (na, Switzerland)
Authors
  • All Speakers (na, Switzerland)